Abstract
A dearth of biologics have been developed and used as therapeutics for numerous disease indications, including IgG monoclonal antibodies, non-IgG recombinant proteins, bi- and multi-specific antibodies, and antibody drug conjugates. A remarkable portion of these biologic constructs exhibits a short plasma half-life that results in a significant reduction in therapeutic efficacy. Frequently, biologic drugs need to be designed to maintain the effective concentration range during the therapeutic window with an extended serum half-life . Provided here is a comprehensive overview of various half-life extension methods involving FcRn engagement, chemical and genetic fusion, post-translational modifications and formulation .
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Walsh G. Biopharmaceutical benchmarks. Nat Biotechnol. 2010;28:917–24.
Scott AM, Wolchok JD, Old LJ. Antibody therapy of cancer. Nat Rev Cancer. 2012;12:278–87.
Kontermann RE. Strategies for extended serum half-life of protein therapeutics. Curr Opin Biotech. 2011;22:868–76.
Ghetie V, Hubbard JG, Kim JK, Tsen MF, Lee Y, Ward ES. Abnormally short serum half-lives of IgG in β2-microglobulin-deficient mice. Eur J Immunol. 1996;26:690–6.
Tesar DB, Bjorkman PJ. An intracellular traffic jam: Fc receptor-mediated transport of Immunoglobulin G. Curr Opin Struct Biol. 2010;20:226–33.
Roopenian DC, Akilesh S. FcRn the neonatal Fc receptor comes of age. Nat Rev Immunol. 2007;7:715–25.
Sun J, Han SJ, Harris SM, Ketchem RR, Lu J, Michaels ML, Retter MW, Tsai MM. Variant fc-polypeptides with enhanced binding to the neonatal fc receptor. WO2013096221 A1, PCT/US2012/070146;2012.
Sarkar CS, Lowenhaupt K, Horan T, Boone TC, Tidor B, Lauffenburger DA. Rational cytokine design for increased lifetime and enhanced potentcy using pH-activated histidine switching. Nat Biotechnol. 2002;20:908–13.
Igawa T, Ishii S, Tachibana T, Maeda A, Higuchi, Shimaoka S, Moriyama C, Watanabe T, Takubo R, Doi Y et al. Antibody recycling by engineered pH-dependent antigen binding improves the duration of antigen neutralization. Nat Biotechnol. 2010;28:1203–1208.
Tang L, Persky AM, Hochhaus G, Meibohm B. Pharmacokinetic aspects of biotechnology products. J Pharmaceut Sci. 2004;93:2184–204.
Tryggvason K, Wartiovaara K. How does the kidney filter plasma? Physiology. 2005;20:96–101.
Gramppa G, Kozakb RW, Schreitmuellerc T. Policy considerations for originator and similar biotherapeutic products. Pharm Policy Law. 2016;18:121–39.
World Heath Organization. Regulatory expectations and risk assessment for biotherapeutic products. WHO/RRA BT_DRAFT/24; January 2014.
Kristoffersen EK. Human placental Fcγ-binding proteins in the maternofetal transfer of IgG. APMIS Suppl. 1996;64:5–36.
Simister NE, Mostov KE. An Fc receptor structurally related to MHC class I antigens. Nature. 1989;337:184–7.
Ober RJ, Martinez C, Lai X, Zhou J, Ward ES. Exocytosis of IgG as mediated by the receptor, FcRn: an analysis at the single-molecule level. Proc Natl Acad Sci USA. 2004;11076–11081.
Burmeister WP, Gastinel LN, Simister NE, Blum ML, Bjorkman PJ. Crystal structure at 2.2 Å resolution of the MHC-related neonatal Fc receptor. Nature. 1994;372:336–43.
Ahouse JJ, et al. Mouse MHC class I-like Fc receptor encoded outside the MHC. J Immunol. 1993;151:6076–88.
West AP, Herr AB, Bjorkman PJ. The chicken yolk sac IgY receptor, a functional equivalent of the mammalian MHC-related Fc receptor, is a phospholipase A2 receptor homolog. Immunity. 2004;20:601–10.
Vaughn DE, Bjorkman PJ. Structural basis of pH-dependent antibody binding by the neonatal Fc receptor. Structure. 1998;6:63–73.
Strohl WR. Fusion proteins for half-life extension of biologics as a strategy to make biobetters. BioDrugs. 2015;29:215–39.
Qiu Y, Lv W, Xu M, Xu Y. Single chain antibody fragments with pH dependent binding to FcRn enabled prolonged circulation of therapeutic peptide in vivo. J Control Release. 2016;229:37–47.
Huang C. Receptor-Fc fusion therapeutics, traps, and MIMETIBODY technology. Curr Opin Biotechnol. 2009;20:692–9.
Kontermann RE. Therapeutic proteins: strategies to extend plasma half-lives of recombinant antibodies. Wiley-VCH;2012. p. 158–62.
Suzuki T, Watabe AI, Tada M, Kobayashi T, Kanayasu-Toyoda T, Kawanishi T, Yamaguchi T. Importance of neonatal FcR in regulating the serum half-life of therapeutic proteins containing the Fc domain of human IgG1: a comparative study of the affinity of monoclonal antibodies and Fc-fusion proteins to human neonatal FcR. J Immunol. 2010;184:1968–76.
Shields RL, et al. High resolution mapping of the binding site on human IgG1 for FcγRI, FcγRII, FcγRIII, and FcRn and design of IgG1 variants with improved binding to the FcγR. J Biol Chem. 2001;276:6591–604.
Petkova SB, et al. Enhanced half-life of genetically engineered human IgG1 antibodies in a humanized FcRn mouse model: potential application in humorally mediated autoimmune disease. Int Immunol. 2006;18:1759–69.
Hinton PR, et al. Engineered human IgG antibodies with longer serum half-lives in primates. J Biol Chem. 2004;279:6213–6.
Kamei DT, et al. Quantitative methods for developing Fc mutants with extended half-lives. Biotechnol Bioeng. 2005;92:748–60.
Vaccaro C, Zhou J, Ober RJ, Ward ES. Engineering the Fc region of immunoglobulin G to modulate in vivo antibody levels. Nat Biotechnol. 2005;23:1283–8.
Dall’Acqua WF, Kiener PA, Wu H. Properties of human IgG1 s engineered for enhanced binding to the neonatal Fc receptor (FcRn). J Biol Chem. 2006;281:23514–24.
Hinton PR, et al. An engineered human IgG1 antibody with longer serum half-life. J Immunol. 2006;176:346–56.
Yeung YA, et al. Engineering Human IgG1 Affinity to Human Neonatal Fc Receptor: Impact of Affinity Improvement on Pharmacokinetics in Primates. J Immunol. 2009;182:7663–71.
Raghavan M, et al. Analysis of the pH dependence of the neonatal Fc receptor/ immunoglobulin G interaction using antibody and receptor variants. Biochemistry. 1995;34:14649–57.
Kim JK, et al. Mapping the site on human IgG for binding of the MHC class I-related receptor, FcRn. Eur J Immunol. 1999;29:2819–25.
Firan M, et al. The MHC class I-related receptor, FcRn, plays an essential role in the maternofetal transfer of -globulin in humans. Int Immunol. 2001;13:993–1002.
Kamei DT, et al. Quantitative methods for developing Fc mutants with extended half-lives. Bioeng. 2005;92:748–60.
Stern M, Herrmann R. Overview of monoclonal antibodies in cancer therapy: present and promise. Crit Rev Oncol Hematol. 2005;54:11–29.
Kenanova V, et al. Tailoring the pharmacokineticsand positron emission tomography imaging properties of anti-carcinoembryonic antigen single-chain Fv-Fc antibody fragments. Cancer Res. 2005;65:622–31.
Datta-Mannan A, et al. Humanized IgG1 variants with differential binding properties to the neonatal Fc receptor: relationship to pharmacokinetics in mice and primates. Drug Metab Dispos. 2007;35:86–94.
Gurubaxani BM, et al. Analysis of a family of antibodies with different half-lives in mice fails to find a correlation between affinity for FcRn and serum half-life. Mol Immunol. 2006;43:1462–73.
Gurubaxani BM, et al. Development of new models for the analysis of Fc–FcRn interactions. Mol Immunol. 2006;43:1379–89.
Borrok MJ, et al. pH-dependent binding engineering reveals an fcrn affinity threshold that governs IgG recycling. J Biol Chem. 2015;290:4282–90.
Ward ES1, Ober RJ. Multitasking by exploitation of intracellular transport functions the many faces of FcRn. Adv Immunol. 2009;103:77–115.
Dall’Acqua WF, et al. Increasing the affinity of a human IgG1 for the neonatal Fc receptor: biological consequences. J Immunol. 169:5171–80.
Yeung YA, et al. A therapeutic anti-VEGF antibody with increased potency independent of pharmacokinetic half-life. Cancer Res. 2010;70:3269–77.
Andersen JT, Sandlie I. The versatile MHC class I-related FcRn protects IgG and albumin from degradation: implications for development of new diagnostics and therapeutics. Drug Metab Pharmacokinet. 2009;24:318–32.
Chaudhury C, et al. Albumin binding to FcRn: distinct from the FcRn-Igg interaction. 2006. Biochemistry. 2006;45:4983–90.
Duttaroy A, et al. Development of a long-acting insulin analog using albumin fusion technology. Diabetes. 2005;54:251–8.
Weimer T, et al. Prolonged in-vivo half-life of factor VIIa by fusion to albumin. Thromb Haemost. 2008;99:659–67.
Müller Dafne, et al. Improved pharmacokinetics of recombinant bispecific antibody molecules by fusion to human serum albumin. J Biol Chem. 2007;282:12650–60.
Chuang VTG, Kragh-Hansen U, Otagiri M. Pharmaceutical strategies utilizing recombinant human serum albumin. Pharm Res. 2002;19:569–77.
Rustgi VK, et al. Albinterferon alf-2b, a novel fusion protein of human albumin and human interferon alf-2b, for chronic hepatitis C. Curr Med Res Opin. 2009;25:991–1002.
Nelson DR, et al. Albinterferon alfa-2b was not inferior to PEGylated interferon-a in a randomized trial of patients with chronic hepatitis C virus genotype 2 or 3. Gastroenterology. 2010;139:1267–76.
Schulte S, et al. Half-life extension through albumin fusion technologies. Thromb Res. 2009;124:S6–8.
Metzner HJ, et al. Genetic fusion to albumin improves the pharmacokinetic properties of factor IX. Thromb Haemost. 2009;102:634–44.
Müller D, et al. Improved pharmacokinetics of recombinant bispecific antibody molecules by fusion to human serum albumin. J Biol Chem. 2007;282:12650–60.
Yazaki PJ, et al. Biodistribution and tumor imaging of an anti-CEA single-chain antibody- albumin fusion protein. Nucl Med Biol. 2008;35:151–8.
Evans L, et al. The production, characterisation and enhanced pharmacokinetics of scFv- albumin fusions expressed in Saccharomyces cerevisiae. Protein Expr. 2010;73:113–24.
Kenanova VE, et al. Tuning the serum persistence of human serum albumin domain III: diabody fusion proteins. Protein Eng Des Sel. 2010;23:789–98.
Xie D, et al. An albumin-conjugated peptide exhibits potent anti-HIV activity and long in vivo half-life. Antimicrob Agents Chemother. 2010;54:191–6.
Kontermann RE. Therapeutic proteins: Strategies to Extend Plasma Half-Lives of Recombinant Antibodies. Wiley-VCH;2012. p. 223–242.
Stork R, Müller D, Kontermann RE. A novel tri-functional antibody fusion protein with improved pharmacokinetic properties generated by fusing a bispecific single-chain diabody with an albumin-binding domain from streptococcal protein G. Protein Eng Des Sel. 2007;20:569–76.
Hopp J, et al. The effects of affinity and valency of an albumin-binding domain (ABD) on the half-life of a single- chain diabody-ABD fusion protein. 2010. Protein Eng Des Sel. 2010;23:827–34.
Stork R, et al. Biodistribution of a bispecific single-chain diabody and its half-life extended derivatives. J Biol Chem. 2009;284:25612–9.
Sand KMK, et al. Dissection of the neonatal Fc receptor (FcRn)-albumin interface using mutagenesis and anti-fcrn albumin-blocking antibodies. J Biol Chem. 2014;289:17228–39.
Löfbloma J, et al. Affibody molecules: Engineered proteins for therapeutic, diagnostic and biotechnological applications. FEBS Lett. 2010;584(12):2670–2680.
Roovers RC, et al. Efficient inhibition of EGFR signalling and of tumour growth by antagonistic anti-EGFR nanobodies. Cancer Immunol Immunother. 2007;56:303–17.
Tijink BM, et al. Improved tumor targeting of anti-epidermal growth factor receptor nanobodies through albumin binding: taking advantage of modular nanobody technology. Mol Cancer Ther. 2008;7:2288–97.
Holt LJ, et al. Anti-serum albumin domain antibodies for extending the half-lives of short lived drugs. Protein Eng Des Sel. 2008;21:283–8.
Walker A, et al. Anti-serum albumin domain antibodies in the development of highly potent, efficacious and long-acting interferon. Protein Eng Des Sel. 2010;23:271–8.
Dennis MS, et al. Albumin Binding as a General Strategy for Improving the Pharmacokinetics. J Biol Chem. 2002;277:35035–43.
Petersen CE, et al. A Dynamic Model for Bilirubin Binding to Human Serum Albumin. J Biol Chem. 2000;275:20985–95.
Kontermann RE. Therapeutic proteins: Strategies to Extend Plasma Half-Lives of Recombinant Antibodies. Wiley-VCH;2012. p. 269–294.
Havelund S, et al. The mechanism of protraction of insulin detemir, a long-acting, acylated analog of human insulin. Pharm Res. 2004;21:1498–504.
Owens DR et al. Pharmacokinetics of 125I-labeled insulin glargine (HOE 901) in healthy men: comparison with NPH insulin and the influence of different subcutaneous injection sites. Diabetes Care. June 23 2000;813–819.
Dumelin CE, et al. A portable albumin binder from a DNA-encoded chemical library. Angew Chem Int Ed. 2008;47:3196–201.
Trussel S, et al. New strategy for the extension of the serum half-life of antibody fragments. Bioconjug Chem. 2009;20:2286–92.
Brocchini S, et al. Disulfide bridge based PEGylation of proteins. Adv Drug Deliv Rev. 2008;60:3–12.
Gaberc-Porekar V, et al. Obstacles and pitfalls in the PEGylation of therapeutic proteins. Curr Opin Drug Discov. 2008;11:242–50.
Jevsevar S1, Kunstelj M, Porekar VG. PEGylation of therapeutic proteins. Biotechnol. J. 2010;5:113–28.
Turecek PL, Bossard MJ, Schoetens F, Ivens IA. PEGylation of biopharmaceuticals: a review of chemistry and nonclinical safety information of approved drugs. J Pharm Sci. 2016;105:460–75.
El-Komy MH1, Widness JA, Veng-Pedersen P. Pharmacokinetic analysis of continuous erythropoietin receptor activator disposition in adult sheep using a target-mediated, physiologic recirculation model and a tracer interaction methodology. Drug Metab Dispos. 2011;39:603–9.
Pegasys—European Medicines Agency—Europa. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR__Product_Information/human/000395/WC500039195.pdf.
PegIntron—European Medicines Agency—Europa. http://www.ema.europa.eu/docs/en_GB/document_library/EPARProduct_Information/human/000280/WC500039388.pdf.
Kinstler O, Molineux G, Treuheit M, Ladd D, Gegg C. Mono-N-terminal poly (ethylene glycol)-protein conjugates. Adv Drug Deliv Rev. 2002;54:477–85.
Molineux G. The design and development of PEGfilgrastim (PEG-rmetHuG-CSF, Neulasta). Curr Pharm Des. 2004;10:1235–44.
Means GE, Feeney RE. Reductive alkylation proteins. Anal Biochem. 1995;224:1–16.
Veronese FM, Mero A. The impact of PEGylation on biological therapies. BioDrugs. 2008;22:315–29.
Veronese FM. Peptide and protein PEGylation: a review of problems and solutions. Biomaterials. 2001;22:405–17.
Roberts MJ, Bentley MD, Harris JM. Chemistry for peptide and protein PEGylation. Adv Drug Deliv Rev. 2002;54:459–76.
Schellenberger V, et al. A recombinant polypeptide extends the in vivo half-life of peptides and proteins in a tunable manner. Nat Biotechnol. 2009;27:1186–90.
Geething NC, et al. Gcg-XTEN: an improved glucagon capable of preventing hypoglycemia without increasing baseline blood glucose. PLoS ONE 2010;5:e10175.
Baker JL, et al. Expanding the glycoengineering toolbox: the rise of bacterial N-linked protein glycosylation. Trends Biotechnol. 2013;31:313–23.
Sola RJ, Griebenow K. Glycosylation of therapeutic proteins: an effective strategy to optimize efficacy. BioDrugs. 2010;24:9–21.
Elliott S, et al. Enhancement of therapeutic protein in vivo activities through glycoengineering. Nat Biotechnol. 2003;21:414–21.
Stork R, et al. N-glycosylation as novel strategy to improve pharmacokinetic properties of bispecific single-chain diabodies. J Biol Chem. 2008;283:7804–12.
Fares FA, et al. Design of a long-acting follitropin agonist by fusing the C-terminal sequence of the chorionic gonadotropin beta subunit to the follitropin beta subunit. Proc Natl Acad Sci U S A. 1992;89:4304–8.
LaPolt PS, et al. Enhanced stimulation of follicle maturation and ovulatory potential by long acting follicle-stimulating hormone agonists with extended carboxyl-terminal peptides. Endocrinology. 1992;131:2514–20.
Agreda-Vasquez GP, et al. Starch and albumin mixture as replacement fluid in therapeutic plasma exchange is safe and effective. J Clin Apher. 2008;23:163–7.
Elliott S, et al. Control of rHuEPO biological activity: The role of carbohydrate. Exp Hematol. 2004;32:1146–55.
Constantinou A, et al. Site-specific polysialylation of an antitumor single-chain Fv fragment. Bioconjug Chem. 2009;20:924–31.
Akbarzadeh A, et al. Liposome: classification, preparation, and applications. Nanoscale Res Lett. 2013;8:102–10.
Immordino ML, Dosio F, Cattel L. Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. Int J Nanomedicine. 2006;1:297–315.
Nag OK, Awasthi V. Surface engineering of liposomes for stealth behavior. Pharmaceutics. 2013;5:542–69.
Yatuv R, Robinson M, Dayan I, Baru M. The use of PEGylated liposomes in the development of drug delivery applications for the treatment of hemophilia. Int J Nanomedicine. 2010;5:581–91.
Yatuv R, Robinson M, Dayan I, Baru M. Enhancement of the efficacy of therapeutic proteins by formulation with PEGylated liposomes; a case of FVIII, FVIIa and G-CSF. Expert Opin Drug Deliv. 2010;7:187–201.
Talelli M, et al. Core-crosslinked polymeric micelles: principles, preparation, biomedical applications and clinical translation. Nano Today. 2015;10:93–117.
Allouche J. Chapter 2: synthesis of organic and bioorganic nanoparticles: an overview of the preparation methods. In: Brayner R, et al., editors. Nanomaterials: a danger or a promise? London:Springer-Verlag;2013.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 American Association of Pharmaceutical Scientists
About this chapter
Cite this chapter
Sun, J., Michaels, M. (2018). Novel Constructs—Half-Life Extensions. In: Warne, N., Mahler, HC. (eds) Challenges in Protein Product Development. AAPS Advances in the Pharmaceutical Sciences Series, vol 38. Springer, Cham. https://doi.org/10.1007/978-3-319-90603-4_23
Download citation
DOI: https://doi.org/10.1007/978-3-319-90603-4_23
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-90601-0
Online ISBN: 978-3-319-90603-4
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)